IVDs For Presence of Biothreats Should Evaluate Animal Specimens - FDA
This article was originally published in The Gray Sheet
Executive Summary
Developers of in vitro diagnostic tests for identification of biothreat agents should evaluate animal specimens and spiked plasma when seeking FDA approval, according to FDA's Microbiology Devices Panel.
You may also be interested in...
ANALYTE SPECIFIC REAGENT LABELING CHANGES DUE BY NOV. 1998 UNDER FDA FINAL RULE; ASR MANUFACTURERS TO BE RESPONSIBLE FOR PREMARKET FILINGS, FDAers SAY
Analyte specific reagent manufacturers have until Nov. 23, 1998 to meet labeling and other requirements of the ASR final rule published by FDA Nov. 21. The one-year phase-in gives firms the opportunity to "deplete their current stock of labels," the agency explains.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.